Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

CardioMEMS cuts heart failure hospitalizations in post-approval study

Key clinical point: Regular collection and use of noninvasive pulmonary artery pressure data cut heart failure hospitalizations among patients with class III disease.

Major finding: Heart failure hospitalizations fell by 58% during the year following CardioMEMS placement compared with the year prior to placement.

Study details: The CardioMEMS Post-Approval Study, with 1,200 heart failure patients at 104 U.S. centers.

Disclosures: The study was sponsored by Abbott, the company that markets the CardioMEMS HF System. Dr. Shavelle has been a consultant to and speaker on behalf of Abbott Vascular and has received research funding from Abbott Vascular, Abiomed, Biocardia, and V-Wave.


Shavelle DM, et al. American College of Cardiology annual meeting, abstract 405-16.